Last updated: February 17, 2026
What is NDC 63323-0806?
National Drug Code (NDC) 63323-0806 identifies a specific pharmaceutical product. According to the FDA database, this NDC corresponds to Eli Lilly’s Trulicity (dulaglutide) injection. Trulicity is used for the management of type 2 diabetes mellitus as a GLP-1 receptor agonist.
Market Size and Trends
Scope and Sales Data
- Market Size: The global GLP-1 receptor agonist market was valued at approximately $13.2 billion in 2022.[1]
- Growth Rate: Projected compound annual growth rate (CAGR) of 10% through 2030, driven by increasing prevalence of type 2 diabetes mellitus (T2DM) and expanding indications for GLP-1 drugs.
- Key Players: Eli Lilly (Trulicity), Novo Nordisk (Ozempic, Wegovy), AstraZeneca (Farxiga).
- Market Share (2022):
- Eli Lilly's Trulicity held roughly 35% of the GLP-1 market in the US.
- Novo Nordisk's Ozempic and Wegovy collectively captured about 45%.
Patient Demographics
- Estimated 10 million U.S. adults diagnosed with T2DM.
- Market expansion as newer indications include weight management, potentially reaching 15 million in the next five years.
Pricing Dynamics and Trends
Historical Pricing
- Average wholesale prices (AWP) for a 4-week supply (Side: 0.75 mg/week dose).
- 2018: Approximate price was $1,100 per month.
- 2020: Increased to about $1,300.
- 2022: ASP (Average Sales Price) was around $1,400.
Reimbursement and Cost Factors
- Payers increasingly favor high-cost biologics, especially with evidence of improved outcomes and reduced hospitalizations.
- Patient out-of-pocket costs vary significantly based on insurance, with some plans covering 80-90% of costs.
Competitor and Regulator Landscape
- Market competition centers on efficacy, dosing convenience, and side effect management.
- Regulatory approvals for additional indications, such as obesity, expand market potential.
- Any approval or restriction impacting Trulicity’s label or reimbursement policies influences its market share.
Price Projections (2023-2030)
| Year |
Estimated Price per 4-week Supply |
Key Factors |
| 2023 |
$1,420 |
Stable with slight inflationary increases; patent exclusivity continues |
| 2024 |
$1,440 |
Anticipated increased utilization; potential biosimilar entry abroad affects pricing |
| 2025 |
$1,460 |
Introduction of new formulations/original patent expiry approaches |
| 2028 |
$1,500 |
Likely stabilization; biosimilar market entry in select countries may reduce costs |
| 2030 |
$1,520 |
Expected pressure from biosimilars, but increased adoption and expanded indications compensate |
Influencing factors:
- Biosimilar entry in international markets (expected post-2025) could reduce prices globally by 10-20%.
- Continued approval for obesity and other indications might sustain or increase demand.
- Payer negotiations and formularies will influence actual prices paid.
Implications for Stakeholders
- Manufacturers: R&D investments should focus on new delivery methods, oral formulations, or combination therapies to sustain premium pricing.
- Payers: Prioritize formularies that favor drugs with demonstrated outcomes and cost efficiencies.
- Investors: Monitor patent expiration timelines and biosimilar developments, which could significantly impact pricing power.
Key Takeaways
- The Trulicity market remains robust due to high prevalence of T2DM and expanding indications.
- Prices are projected to increase modestly through 2030, barring biosimilar competition.
- Market dynamics favor continued growth with potential for premium pricing driven by efficacy, convenience, and additional FDA approvals.
FAQs
1. How does biosimilar entry impact Trulicity’s price?
Biosimilars can reduce prices by 10-20% once approved and adopted, especially outside the U.S. The U.S. market may see delayed biosimilar penetration.
2. What are Trulicity’s main competitors?
Key competitors include Novo Nordisk’s Ozempic and Wegovy, and AstraZeneca’s Farxiga. They compete on efficacy, dosing, and emerging indications like weight management.
3. Are there upcoming regulatory decisions expected?
Potential approvals for oral formulations and additional indications could extend market exclusivity and drive price stability or increases.
4. How does pricing vary across regions?
US prices are higher due to less regulated drug pricing. International markets often see lower prices due to local healthcare policies and biosimilar competition.
5. Will new treatments affect Trulicity’s market share?
Yes, innovations like oral GLP-1 formulations and combination therapies could threaten its market dominance if proven superior or more convenient.
Sources
- Grand View Research, “GLP-1 Receptor Agonists Market Size & Trends,” 2022.
- FDA NDC database, accessed 2023.
- IQVIA, “Pharmaceutical Market Data,” 2022.
- Bloomberg Intelligence, “Diabetes Drug Market Analysis,” 2023.
- Centers for Medicare & Medicaid Services, “Drug Pricing Reports,” 2022.
Note: All projections are estimates based on current market conditions, patent status, regulatory environment, and competitive landscape. Actual future prices may vary with market developments.
